Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Seminars in Oncology

Volumn 36, Issue 2, 2009, Pages 112-125

  Martin, Lainie P ^a   Schilder, Russell J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; NAVELBINE; PACLITAXEL; PLATINUM; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN;

ALOPECIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DRUG APPROVAL; DRUG BINDING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; LEUKEMIA; LOW DRUG DOSE; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUROTOXICITY; OVARY CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS;

EID: 62949141270     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.12.003     Document Type: Article

References (120)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer Stat 58 (2008) 71-96
2. Markman M., Reichman B., Hakes T., Jones W., Lewis Jr. J.L., Rubin S., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9 (1991) 1801-1805
3. Gore M.E., Fryatt I., Wiltshaw E., and Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36 (1990) 207-211
4. Blackledge G., Lawton F., Redman C., and Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59 (1989) 650-653
5. Dizon D.S., Dupont J., Anderson S., Sabbatini P., Hummer A., Aghajanian C., et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: the Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 91 (2003) 584-590
6. Parmar MK L.J., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., Wheeler S., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
7. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (2006) 4699-4707
8. Orlando M., Costanzo M.V., Chacon R.D., and Tajer C.D. Randomized trials of combination chemotherapy (combo) versus monotherapy (mono) in relapsed ovarian carcinoma (ROC): a meta-analysis of published data. [abstract]. J Clin Oncol 25 Suppl (2007) 5524 (meeting abstracts)
9. Ferrero J.M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2007) 263-268
10. du Bois A., Pfisterer J., Burchardi N., Loibl S., Huober J., Wimberger P., et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 107 (2007) 518-525
11. Alberts D.S., Liu P.Y., Wilczynski S.P., Clouser M.C., Lopez A.M., Michelin D.P., et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 108 (2008) 90-94
12. Gordon A.N., Granai C.O., Rose P.G., Hainsworth J., Lopez A., Weissman C., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18 (2000) 3093-3100
13. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78 (2000) 369-372
14. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 (1997) 987-993
15. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
16. Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26 (2008) 890-896
17. Gordon A.N., Tonda M., Sun S., and Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 (2004) 1-8
18. O'Byrne K.J., Bliss P.B., Graham J.D., Gerber J., Vasey P.A., Khanna S., et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. [abstract]. Proc Am Soc Clin Oncol 21 (2002) 808
19. Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D., et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25 (2007) 2811-2818
20. Bilgin T.O.S., Yalçin O.T., Zorlu G., Vardar M.A., and Ozerkan K. Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Eur J Gynaecol Oncol 24 (2003) 169-170
21. D'Agostino G., Amant F., Berteloot P., Scambia G., and Vergote I. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88 (2003) 266-269
22. Friedlander M., Millward M.J., Bell D., Bugat R., Harnett P., Moreno J.A., et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9 (1998) 1343-1345
23. Lund B., Hansen O.P., Theilade K., Hansen M., and Neijt J.P. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86 (1994) 1530-1533
24. Markman M., Webster K., Zanotti K., Kulp B., Peterson G., and Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90 (2003) 593-596
25. Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63 (1996) 89-93
26. Silver D.F., and Piver M.S. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 22 (1999) 450
27. Minckwitz G., Bauknecht T., Visseren-Grul C.M., and Neijt J.P.D. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 10 (1999) 853-855
28. Nelson R., and Tarassoff P. Dyspnoea with gemcitabine is commonly seen, often disease related, transient, and rarely severe. Eur J Cancer 31 Suppl 6 (1995) S197-S198
29. Pavlakis N.B.D., Millward M.J., and Levi J.A. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80 (1997) 286-291
30. McGuire W.P., Rowinsky E.K., Rosenshein N.B., Grumbine F.C., Ettinger D.S., Armstrong D.K., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111 (1989) 273-279
31. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., and Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12 (1994) 1748-1753
32. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 23 Suppl 12 (1996) 40-47
33. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
34. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92 (2000) 699-708
35. Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15 (1997) 187-192
36. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20 (2002) 2365-2369
37. Dunder I.B.B., Atabekoglu C., and Bilgin T. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur J Gynaecol Oncol 26 (2005) 79-82
38. Ghamande S., Lele S., Marchetti D., Baker T., and Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 13 (2003) 142-147
39. Kita T., Kikuchi Y., Takano M., Suzuki M., Oowada M., Konno R., et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 92 (2004) 813-818
40. Le T., Hopkins L., Baines K.A., Rambout L., Al Hayki M., and Kee Fung M.F. Prospective evaluationsof continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol 102 (2006) 49-53
41. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101 (2006) 436-440
42. Francis P., Schneider J., Hann L., Balmaceda C., Barakat R., Phillips M., et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12 (1994) 2301-2308
43. Kavanagh J.J., Kudelka A.P., de Leon C.G., Tresukosol D., Hord M., Finnegan M.B., et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2 (1996) 837-842
44. Piccart M.J., Gore M., Huinink W.T.B., Van Oosterom A., Verweij J., Wanders J., et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87 9 (1995) 676-681
45. Katsumata N., Tsunematsu R., Tanaka K., Terashima Y., Ogita S., Hoshiai H., et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann Oncol 11 (2000) 1531-1536
46. Berkenblit A., Seiden M.V., Matulonis U.A., Penson R.T., Krasner C.N., Roche M., et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 95 (2004) 624-631
47. Komiyama S.T.H., Asai S., Dokoh J., Ishikawa M., and Mikami M. A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur J Gynaecol Oncol 26 (2005) 299-302
48. Tinker A.V., Gebski V., Fitzharris B., Buck M., Stuart-Harris R., Beale P., et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecol Oncol 104 (2007) 647-653
49. Hoskins P., Eisenhauer E., Beare S., Roy M., Drouin P., Stuart G., et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16 (1998) 2233-2237
50. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
51. Eckhardt S., Hernádi Z., Thurzó L., Telekes A., Sopkova B., Mechl Z., Pawlicki M., and Kerpel-Fronius S. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) study. Oncology 47 (1990) 289-295
52. Edmonson J.H., Decker D.G., Malkasian G.D., Webb M.J., and Jorgensen E.O. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. Gynecol Oncol 6 (1978) 7-9
53. Maskens A.P., Armand J.P., Lacave A.J., De Jager R.L., Hansen H.H., and Wolff J.P. Phase II clinical trial of VP-16-213 in ovarian cancer. Cancer Treat Rep 65 (1981) 329-330
54. Alici S., Saip P., Eralp Y., Aydiner A., and Topuz E. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol 26 (2003) 358-362
55. de Wit R., van der Burg M.E.L., Gaast A.v.d., Logmans A., Stoter G., and Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 5 (1994) 656-657
56. Hoskins P.J., and Swenerton K.D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12 (1994) 60-63
57. Markman M., Hakes T., Reichman B., Curtin J., Barakat R., Rubin S., et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol. 119 (1992) 55-57
58. Rose P.G., Blessing J.A., Mayer A.R., and Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16 (1998) 405-410
59. Seymour M.T., Mansi J.L., Gallagher C.J., Gore M.E., Harper P.G., Evans T.R., et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer. 69 (1994) 191-195
60. Bajetta E., Di Leo A., Biganzoli L., Mariani L., Cappuzzo F., Di Bartolomeo M., et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 14 (1996) 2546-2551
61. Burger R.A., DiSaia P.J., Roberts J.A., O'Rourke M., Gershenson D.M., Homesley H.D., et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72 (1999) 148-153
62. Sorensen P., Hoyer M., Jakobsen A., Malmstrom H., Havsteen H., and Bertelsen K. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 81 (2001) 58-62
63. Markman M., Kennedy A., Sutton G., Hurteau J., Webster K., Peterson G., et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 70 (1998) 272-274
64. Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol 51 (1993) 104-108
65. Hasan J., and Jayson G.C. Oral melphalan as a treatment for platinum-resistant ovarian cancer. Br J Cancer 88 (2003) 1828-1830
66. Johnson B.L., Fisher R.I., Bender R.A., DeVita Jr. V.T., Chabner B.A., and Young R.C. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer 42 (1978) 2157-2161
67. Keldsen N., Havsteen H., Vergote I., Bertelsen K., and Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol 88 (2003) 118-122
68. Manetta A., Tewari K., and Podczaski E.S. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 66 (1997) 20-26
69. Markman M., Blessing J.A., Moore D., Ball H., and Lentz S.S. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 69 (1998) 226-229
70. Vergote I., Himmelmann A., Frankendal B., Scheistroen M., Vlachos K., and Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 47 (1992) 282-286
71. Chan J.K., Loizzi V., Manetta A., and Berman M.L. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol 92 (2004) 368-371
72. Perez-Gracia J.L., and Carrasco E.M. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 84 (2002) 201-209
73. Agarwal R., Linch M., and Kaye S.B. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 32 (2006) 875-886
74. Bhoola S.M., and Alvarez R.D. Novel therapies for recurrent ovarian cancer management. Expert Rev Anticancer Ther 4 (2004) 437-448
75. Darcy K.M., and Schilder R.J. Relevant molecular markers and targets. Gynecol Oncol 103 Suppl 1 (2006) 6-13
76. See H.T., and Kavanagh J.J. Novel agents in epithelial ovarian cancer. Cancer Invest 22 Suppl 2 (2004) 29-44
77. Martin L., and Schilder R.J. Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. J Natl Compr Cancer Network 4 (2006) 955-966
78. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 5165-5171
79. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 (2007) 5180-5186
80. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. [abstract 2]. J Clin Oncol 23 Suppl 2 (2005) (meeting abstracts)
81. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
82. Sandler A.B., Gray R., Brahmer J., Dowlati A., Schiller J.H., Perry M.C., et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599. [abstract]. J Clin Oncol 23 Suppl (2005) LBA4 (meeting abstracts)
83. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26 (2008) 76-82
84. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., and Fowler J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102 (2006) 134-139
85. Numnum T.M., Rocconi R.P., Whitworth J., and Barnes M.N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102 (2006) 425-428
86. Zebrowski B.K., Liu W., Ramirez K., Akagi Y., Mills G.B., and Ellis L.M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6 (1999) 373-378
87. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
88. Hochster H.S. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin Oncol 33 Suppl 10 (2006) S8-S14
89. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
90. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
91. Fong P.C., Boss D.S., Carden C.P., Roelvink M., De Greve J., Gourley J., et al. A phase I trial of AZD2281 (KU-0059436), a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient tumours, particularly ovarian cancer. [abstract 5510]. J Clin Oncol 26 (2008) May 20 Suppl
92. Ratnam K., and Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13 (2007) 1383-1388
93. Chou H.-H., Wang K.-L., Chen C.-A., Wei L.-H., Lai C.-H., Hsieh C.-Y., et al. Pegylated liposomal doxorubicin (Lipo-Dox(R)) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese Gynecologic Oncology Group study with long-term follow-up. Gynecol Oncol 101 (2006) 423-428
94. Lorusso D.N.A., Testa A., D'Agostino G., Scambia G., and Ferrandina G. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?. Oncology 67 (2004) 243-249
95. Sehouli J., Oskay-Ozcelik G., Kuhne J., Stengel D., Hindenburg H.J., Klare P., et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 17 (2006) 957-961
96. Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Levenback C., Chantarawiroj P., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14 (1996) 1552-1557
97. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14 (1996) 3056-3061
98. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., and Herzog T.J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66 (1997) 480-486
99. Bookman M.A., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J.B., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16 (1998) 3345-3352
100. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 18 (2000) 1062-1067
101. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., and Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 79 (2000) 116-119
102. Brown J.V., Peters W.A., Rettenmaier M.A., Graham C.L., Smith M.R., Drescher C.W., et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 88 (2003) 136-140
103. Homesley H.D., Hall D.J., Martin D.A., Lewandowski G.S., Vaccarello L., Nahhas W.A., et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 83 (2001) 394-399
104. Spannuth W.A., Leath III C.A., Huh W.K., Barnes III M.N., Davidson S.A., Kilgore L.C., et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 104 (2007) 591-595
105. Safra T., Menczer J., Bernstein R., Shpigel S., Inbar M.J., Grisaru D., et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 105 (2007) 205-210
106. Brown III J.V., Rettenmaier M.A., Lopez K.L., Graham C., Micha J.P., and Goldstein B. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer 18 (2008) 249-254
107. Rose P.G., Gordon N.H., Fusco N., Fluellen L., Rodriguez M., Ingalls S.T., et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 78 (2000) 228-234
108. Hochster H., Wadler S., Runowicz C., Liebes L., Cohen H., Wallach R., et al., New York Gynecologic Oncology Group. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 17 (1999) 2553-2561
109. Markman M., Blessing J.A., Alvarez R.D., Hanjani P., Waggoner S., and Hall K. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 77 (2000) 112-115
110. Clarke-Pearson D.L., Van Le L., Iveson T., Whitney C.W., Hanjani P., Kristensen G., et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 19 (2001) 3967-3975
111. du Bois A., Pfisterer J., Burchardi N., Loibl S., Huober J., Wimberger P., et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum. Eur J Cancer 33 (1997) 379-384
112. Nardi M., Aloe A., De Marco S., Cognetti F., Iacovelli A., Atlante G., et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol 20 (1997) 230-232
113. Pectasides D.P.M., Varthalitis J., Mylonakis A., Kostopoulou M., Dimitriadis M., and Athanassiou A. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology. 55 (1998) 228-234
114. Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., and Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 79 (2000) 211-215
115. Cantu M.G., Buda A., Parma G., Rossi R., Floriani I., Bonazzi C., et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (2002) 1232-1237
116. Lorenz E., Hagen B., Himmelmann A., Kjorstad K., Onsrud M., Tingulstad S., et al. A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 9 (1999) 373-376
117. Kaye S., Piccart M., Aapro M., and Kavanagh J. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer 31A Suppl 4 (1995) S14-S17
118. Verschraegen C.F., Sittisomwong T., Kudelka A.P., Guedes EdP., Steger M., Nelson-Taylor T., et al. Docetaxel for patients with paclitaxel-resistant mullerian carcinoma. J Clin Oncol 18 (2000) 2733-2739
119. Rose P.G., Blessing J.A., Ball H.G., Hoffman J., Warshal D., DeGeest K., et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88 (2003) 130-135
120. Markman M., Zanotti K., Webster K., Peterson G., Kulp B., and Belinson J. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 91 (2003) 573-576